Oramed Pharmaceuticals Reduces Stake in Nano Dimension Ltd. Below 5% Threshold

Oramed Pharmaceuticals Inc. has filed Amendment No. 3 to its Schedule 13D, reporting a significant reduction in its position in Nano Dimension Ltd. (NNDM). On July 20, 2026, the Reporting Person executed a block sale of 8,200,000 Ordinary Shares at a price of $1.55 per share. Following this transaction, Oramed's beneficial ownership decreased to 6,879,708 shares, representing approximately 3.3% of the outstanding Ordinary Shares based on the Issuer's share count as of June 23, 2026. Consequently, the Reporting Person has ceased to be a beneficial owner of more than five percent of the Issuer. In addition to the share sale, Oramed disclosed various options activities on July 20, including the purchase of call options for 8,200,000 shares and the sale of put options for 8,200,000 shares. However, the filing notes that following these transactions, the Reporting Person is no longer a party to any options contracts regarding the Ordinary Shares. The total expenditure for the call options was approximately $1.258 million, sourced from general working capital.